Related Experiment Videos
Angiotensin receptor blockers in heart failure
Jan Stergren1, John J V McMurray
1Karolinska Hospital, Stockholm, Sweden.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|November 11, 2003
Summary
Angiotensin receptor blockers (ARBs) offer significant benefits for heart failure patients, improving symptoms and reducing mortality. Adding ARBs to ACE inhibitors further enhances these positive outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Symptomatic heart failure management remains a clinical challenge.
- Angiotensin receptor blockers (ARBs) have emerged as a therapeutic option.
- The role of ARBs in various heart failure patient subsets requires clarification.
Purpose of the Study:
- To evaluate the clinical value of ARBs in patients with symptomatic heart failure.
- To compare the efficacy of ARBs with angiotensin-converting enzyme (ACE) inhibitors.
- To assess the additional benefits of ARBs when combined with ACE inhibitors.
Main Methods:
- Analysis of large, prospective randomized outcome trials.
- Inclusion of patients with diverse background therapies and ventricular function.
- Specific trials examined include Val-HeFT, CHARM-Added, and CHARM-Preserved.
Main Results:
- ARBs demonstrate clinical value across a broad spectrum of heart failure patients.
- ARBs provide a clear benefit for patients intolerant to ACE inhibitors, comparable to ACE inhibitors themselves.
- Adding ARBs to ACE inhibitors significantly reduces symptoms, morbidity, and mortality.
- Candesartan showed potential in reducing heart failure hospital admissions in patients with preserved systolic function.
Conclusions:
- ARBs are a valuable therapeutic class for symptomatic heart failure.
- Combination therapy with ARBs and ACE inhibitors offers additive benefits.
- Further research is needed to confirm ARB efficacy in heart failure with preserved systolic function.